Background. Patients undergoing hemodialysis and kidney graft recipients are high-risk populations for cardiovascular and all-cause mortality. Fibroblast growth factor 23 (FGF23), osteoprotegerin (OPG), RANK ligand, osteopontin (OPN), Klotho protein and bone morphogenetic protein-7 (BMP-7) are boneand vascular-derived molecular biomarkers that have been shown to be associated with cardiovascular surrogate end points; however, currently available data on the prognostic value of these biomarkers is inconsistent. The aim of the present study was to conduct a systematic review and meta-analysis in order to summarize the available evidence on the association of molecular biomarkers with mortality in individuals undergoing hemodialysis and renal transplant patients. Methods. Two databases (MEDLINE and Embase) were systematically searched. Studies were eligible if the association of biomarker and mortality was reported as time-to-event data [hazard Ratio (HR)] or as effect size with a fixed time of follow-up [odds Ratio (OR)]. Abstracted HRs were converted onto a standard scale of effect and combined using a random effects model. Results. From a total of 1170 studies identified in initial searches, 21 met the inclusion criteria. In hemodialysis patients, comparing the lower third with the upper third of baseline FGF23 distribution, pooled HRs (95% confidence intervals) were 1.94 (1.47, 2.56) for all-cause mortality and 2.4 (1.64, 3.51) for cardiovascular mortality. For the same comparison of baseline OPG distribution, pooled HRs were 1.8 (0.95, 3.39) for all-
The pathophysiological mechanisms resulting in an elevated mortality rate among ESRD patients are complex and multifactorial. Calcification of large-and medium-sized arteries, as well as calcification of the cardiac valves, are common findings in chronic kidney disease (CKD) patients and are associated with mortality [8] . The pathogenesis of calcium deposition in the vessel wall is not fully understood; however, the transformation of vascular smooth cells into osteoblast-like cells has been demonstrated to be a key player [9] . Over the past decade, a growing number of bone-and vascular-derived proteins has been identified to be actively involved in the regulation of the calcification process. Fibroblast growth factor 23 (FGF23), osteoprotegerin (OPG), RANK ligand, osteopontin (OPN), Klotho protein and bone morphogenetic protein-7 (BMP-7) are novel molecular biomarkers that have all been shown to be associated with vessel calcification and cardiovascular surrogate end points in CKD patients [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Nevertheless, currently available data on the prognostic value of these biomarkers is inconsistent.
Numerous narrative reviews have addressed the potential relationship of biomarkers of vascular calcification to survival in ESRD patients [23] [24] [25] [26] [27] [28] [29] [30] ; however, a quantitative summary of the present evidence combined in one up to date systematic review and meta-analysis is lacking. The aim of the present study was to summarize the available evidence based on the association of circulating molecular biomarkers of vascular calcification with allcause mortality and death due to cardiovascular events in individuals undergoing hemodialysis and renal transplant patients.
M A T E R I A L S A N D M E T H O D S
The present review was performed in accordance with the MOOSE guidelines for meta-analyses of observational studies [31] and the PRISMA statement [32] .
Data sources and search strategy
A search syntax was constructed with Boolean combinations of terms for kidney transplantation, hemodialysis and circulating bone-and vascular-derived biomarkers to identify studies investigating the association between these biomarkers and mortality in adult ESRD patients who received either a kidney transplant or maintenance hemodialysis in MEDLINE and Embase (last searches on 11 May 2016). Detailed search strategies are described in the Supplementary Data, Appendix S1. Reference lists of included articles were also reviewed for relevant citations.
Study selection and eligibility criteria
Two independent reviewers screened titles and abstracts and further assessed the full text of each potentially relevant study to determine eligibility for inclusion using pre-defined criteria. Disagreements on inclusion/exclusion were resolved through consensus adjudication. Narrative reviews, reports to congress, commentaries, case reports, editorials and publications in languages other than English, German or Spanish were excluded.
Prospective and retrospective cohort studies were eligible for inclusion if they evaluated the association of one or more selected molecular biomarker (FGF23, OPG, RANK ligand, OPN, Klotho protein, BMP-7) with mortality in adult ESRD patients undergoing hemodialysis or in renal transplant patients, regardless of the underlying renal impairment cause. Studies recruiting participants receiving peritoneal dialysis were excluded in order to reduce sample bias, as the baseline characteristics, metabolic profile and mortality risk of these patients differ from patients treated with hemodialysis. No restriction criteria were applied in terms of biomarker assay method or sample type. Studies were further eligible if the association of circulating biomarker and all-cause mortality or cardiovascular mortality (defined as death due to cardiovascular disease) was reported as time-to-event data. Substudies of randomized controlled trials were included if the intervention had no statistically significant impact on the outcome and if the intervention was adjusted for when assessing the relationship between biomarker and mortality. Case-control studies were carefully evaluated and included only if detailed information on the control for potential confounding effects in the control group was provided and a fixed time of follow-up was given [in that case, reported odds ratios (OR) were considered to be representative of hazard ratios (HR)].
Data extraction and quality assessment
A data abstraction form was designed to extract information including study design and size, location, population characteristics, duration of follow-up, total number of events, biomarker concentration, biomarker assay method and quantification of risk. Furthermore, the reported adjustment factors were recorded and adjustment degree was rated as followed: 'þ' for univariate analysis; ' þþ' when adjusted for at least three established cardiovascular risk factors (age, gender, body mass index, smoking status, hypertension, diabetes mellitus, dyslipidemia, baseline cardiovascular disease); ' þþþ' when further adjusted for at least three dialysis-related variables or 'standard' laboratory values (e.g. dialysis vintage, creatinine, albumin, PTH, hemoglobin); ' þþ þþ' when one or more established biomarker of mortality risk (e.g. NTproBNP, troponin, hsCRP) or bone-and vascularderived biomarkers were further adjusted for.
The risk of bias was evaluated using the Newcastle-Ottawa quality assessment scale for cohort studies [33] : the selection of study participants, comparability of study groups and ascertainment of outcome are judged by a star system with a maximum of nine stars. Studies that scored nine stars were rated to be at low risk of bias, a score of seven or eight stars was considered to be at medium risk and a score of six or less stars was rated as high risk of bias (Supplementary Data, Appendix S2).
Data synthesis and analysis
Abstracted data was classified by baseline population (hemodialysis versus graft recipients), biomarker type and outcome (all-cause versus cardiovascular mortality). Studies that met the inclusion criteria but could not be pooled due to insufficient data (less than three studies available addressing the defined intervention and outcome) were summarized qualitatively.
The reported risk estimates for the association between circulating biomarker and mortality outcomes were converted onto a standard scale of effect, comparing the lower third with the upper third of the biomarker distribution of each study. The S y s t e m a t i c r e v i e w o f m o l e c u l a r b i o m a r k e r s a n d m o r t a l i t y i n E S R D p a t i e n t s
reported risk estimates included continuous measures [per one unit, per 1000 units, per log one standard deviation (SD) and per ln one SD] and equal size groups (comparing upper versus lower half, tertile and quartile, respectively), and were transformed according to previously published meta-analyses investigating the prognostic value of circulating continuous measures on mortality [34, 35] . Briefly, the scaling factor for studies comparing equal groups was calculated dividing the difference in means of the upper and lower third of the standard normal distribution (i.e. 2.18) by the difference in means of the upper and lower interval of the reported groups: 2.18/1.59 for studies comparing upper versus lower half and 2.18/2.54 for studies comparing top versus bottom quartile. Corresponding authors were contacted when time-to-event data were not available in the main manuscript or when the conversion of abstracted data contained incertitude. If median and interquartile range were reported, the median was considered to be representative of the mean, a valid option for studies with a sample size > 25 [36] . The maximally adjusted risk ratio was used when multivariate models with various degrees of adjustments were available.
The converted risk estimates were combined using a random effects model that included between study heterogeneity taken from the Mantel-Haenszel model. Data were expressed as HR and 95% confidence intervals. Heterogeneity across studies was assessed by testing with v 2 and the I 2 -statistic, considering I 2 40%, 40-75% and ! 75% as an indication of low, moderate and high variability, respectively [37, 38] . Funnel plots and the Egger test were performed to evaluate publication bias in metaanalysis; however, the accuracy of these tests is low or may even be misleading when fewer than 10 studies are available for quantitative summary [39] .
All statistical analyses were performed with Stata/SE 12.0 (StataCorp). Tests were two sided and a P-value <0.05 was considered statistically significant throughout the manuscript.
R E S U L T S
The search strategy yielded 1770 potentially relevant citations from electronic databases. After removal of 519 duplicates, a total of 1251 citations were screened based on titles and abstracts. A total of 179 articles remained for full-text eligibility assessment, of which 158 were excluded due to inappropriate study population, intervention, outcome, study design, article type or data report (Figure 1) . A total of 21 articles met the inclusion criteria and were included in the meta-analysis (Tables 1 and 2 ).
Relationship of biomarkers with mortality in patients undergoing hemodialysis
A total of 16 studies reported all-cause mortality risk in relation to biomarker concentration involving 5096 patients who experienced 2277 events [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] . Regarding cardiovascular mortality, eight studies including 1812 patients who suffered S y s t e m a t i c r e v i e w o f m o l e c u l a r b i o m a r k e r s a n d m o r t a l i t y i n E S R D p a t i e n t s 471 events were analyzed [40, 48, 49, [51] [52] [53] [54] 56] . In seven out of these eight studies, data on all-cause and cardiovascular mortality was assessed in the same baseline population but reported separately. Regarding demographic distribution, six studies were located in the USA and Canada, six in Eastern Asia (Japan, China, Taiwan and Korea) and four in Europe (France, Germany, Denmark). In one article the authors did not provide detailed information on the study location [56] .
FGF23 and OPG were summarized quantitatively; for the remaining biomarkers there were too few studies to warrant meta-analysis.
FGF23.
A total of 11 studies were included in meta-analysis, four of which reported data separately on cardiovascular mortality [40-45, 47, 50, 51, 53, 54] .
For all-cause mortality, 11 studies that recruited 3855 patients (mean age 61.4 years; mean proportion of males 59.3%; mean dialysis vintage 4 years) were included for quantitative summary. During a mean follow-up of 3.01 years, 1641 deaths from any cause occurred. In comparisons of patients in the bottom versus top thirds of the population distributions, the pooled HR (95% confidence interval) of baseline circulating FGF23 concentrations for all-cause mortality was 1.94 (1.47, 2.56) (Figure 2A) . Heterogeneity between included studies was borderline significant (I 2 ¼ 55.7%, v 2 ¼ 22.59, P ¼ 0.012). Publication bias was assessed by performing a funnel plot, which did not show asymmetry (Supplementary Figure S1) ; likewise, Egger's test for asymmetry was not significant (P-value 0.472). One study assessed both C-terminal and intact FGF23 and reported the results separately [42] . When intact FGF23 instead of C-terminal FGF23 was included in the forest plot, the pooled HR was 1 Figures S4a-S4d) . Sensitivity analysis was performed by sequentially eliminating studies from the overall model; substantial changes were not observed (data not shown).
Regarding cardiovascular mortality, four studies that recruited 776 patients (mean age 59.4 years, mean proportion of males 56.7%, mean dialysis vintage 4.4 years) were summarized [40, 51, 53, 54] . A total of 245 deaths due to cardiovascular events occurred during a mean follow-up time of 4.2 years. For the comparison of the lower versus the upper population distribution, pooled HR for cardiovascular death was 2.4 (1.64, 3.51) ( Figure 2B) . Heterogeneity between studies and publication bias was not significant (I 2 ¼ 0%, v 2 ¼ 1.76, p ¼ 0.624 and Egger's P-value for asymmetry 0.853) (Supplementary Figure  S5) ; likewise, no significant changes were observed in sensitivity analysis.
OPG. Five out of six studies were included for quantitative summary, three of which reported data separately for cardiovascular mortality [46, 48, 49, 52, 55, 56] .
For all-cause mortality, a total of 1241 patients (mean age 62 years; mean proportion of males 56.1%; mean dialysis vintage 5.2 years) was identified in five studies. During a mean followup period of 3.3 years 636 events were reported. The pooled HR (95% confidence interval) for all-cause mortality of circulating OPG levels in comparison of the bottom versus the top third of population distribution was 1.8 (0.95, 3.39) ( Figure 3A) . Substantial heterogeneity between studies was observed (I 2 ¼ 85.6%, v 2 ¼ 27.86, P < 0.001). Sensitivity analysis showed a significant association between OPG and all-cause mortality when the study conducted by Lee et al. [46] Figure 3B ). Heterogeneity between studies was significant (I 2 ¼ 74%, v 2 ¼ 7.68, P ¼ 0.021). One study reported the risk for cardiovascular mortality as HR for the increase of one ln-transformed OPG unit [56] and was not included in the quantitative summary because the abstracted data could not be converted onto a standard scale of effect; however, the authors reported a HR of 7.17 (1.89, 27.25) for "high" OPG levels.
Klotho protein. The association of Klotho protein with allcause and cardiovascular mortality was investigated in one study from Japan involving 63 patients undergoing hemodialysis followed for 5.4 years [51] . Circulating Klotho protein levels were related to all-cause mortality comparing the bottom versus the top third of the population distribution [HR (95% confidence interval) 5 One study from Germany followed 239 patients for 2.5 years and found no significant association between Klotho protein and all-cause mortality comparing the lower and the upper third of the population distribution [HR 2.42 (1, 5.87); 59 events] in multivariate models [50] . Neither study adjusted for FGF23 levels. OPN and BMP-7. One study from the USA met the inclusion criteria for the present review [52] . A total of 602 hemodialysis patients were prospectively followed for 3.4 years and the association of circulating biomarkers with all-cause mortality (423 events) and/or cardiovascular mortality (186 events) was assessed comparing the upper versus the lower tertile of the population distribution. OPN and BMP-7 did not show a significant relationship with death from any cause [HR (95% confidence interval) 1.06 (0.77, 1.45) and 1.01 (0.74, 1.35), respectively].
Relationship of biomarkers with mortality in renal transplant patients
A total of four studies met the inclusion criteria of the present systematic review [57] [58] [59] [60] . The association of FGF23 FGF23. In the Netherlands, 593 patients were followed during 7 years and comparison of the bottom versus the top third of the population distribution showed significant association for FGF23 and both all-cause mortality [HR 2.23 (95% confidence interval) ( OPG. In one large multicentric substudy, a total of 1889 patients was recruited and followed during 6.7 years [59] . [58] .
Methodological quality
Overall, the studies that were integrated in the meta-analysis showed a medium risk for bias according to the NewcastleOttawa quality assessment scale for cohort studies ('Study Quality' in Figures 2 and 3) . Out of the 16 articles that addressed all-cause mortality among hemodialysis patients, 1 study scored the maximum of nine stars, whereas 10 studies were rated with eight and 5 studies with seven stars, respectively. No included article scored six or less stars. For cardiovascular mortality, six studies were rated with eight stars and two studies scored seven stars.
Adjustment degree was moderate, with marked differences among the variables that were controlled for in multivariate models (Supplementary Table S1 ). Among the studies that investigated all-cause mortality in hemodialysis patients, two studies scored the maximum of ' þþ þþ', eight studies were rated ' þþþ', four studies scored ' þþ' and univariate analysis was performed in two studies. For cardiovascular mortality, no study reached the maximum score, three studies were rated ' þþþ' and ' þþ', respectively, and two studies reported the risk in univariate models.
For data in renal transplant patients, two studies reporting association between FGF23 and mortality scored nine and seven stars on the Newcastle-Ottawa quality assessment scale for cohort studies, respectively, whereas both studies that investigated OPG scored seven stars. Adjustment degrees were rated ' þþ þþ' and ' þþ' in the FGF23-reporting studies, respectively, and the OPG-reporting studies scored ' þþþ' and ' þþ', respectively.
In all studies, ELISA was used for the measurement of biomarker concentrations with assay kits from several different manufacturers (Tables 1 and 2 ). Biomarkers were assessed in plasma (nine studies) and serum (nine studies), whereas no detailed information on the biomarker sample type was given in three studies (Supplementary Table S1 ). Biomarker units and reported distributions were not uniform, hence, mean baseline biomarker concentrations showed a broad distribution (Tables 1 and 2 ).
D I S C U S S I O N
The present systematic review and meta-analysis shows that baseline FGF23 concentration is associated with a higher risk (approximately 2-fold) for all-cause and cardiovascular mortality in ESRD patients receiving hemodialysis when the upper versus the lower third of biomarker distribution is compared. For the same comparison, circulating OPG levels are related to cardiovascular mortality but not to death from any cause in the investigated population setting. Currently available evidence on the association of RANK ligand, OPN, Klotho protein and BMP-7 with mortality in individuals undergoing dialysis is scarce and not suitable for pooling of risk ratios; however, among these biomarkers only Klotho protein was reported to be related to mortality.
For kidney graft recipients, a formal integration of available studies in one meta-analysis was not possible due to the lack of comprehensive data. The systematic search yielded four studies that investigated the relationship of FGF23 and OPG with mortality, all of which reported a significant association. Nevertheless, a quantitative summary of the relationship of biomarkers of vascular calcification with mortality in renal transplant patients remains an unmet need.
The main finding of the present systematic review is comparable to a previously published meta-analysis on the association of FGF23 with mortality [61] . Xiao et al. reported an increase in the relative risk for death from any cause and cardiovascular mortality of 34% and 24%, respectively, with 'high' levels of FGF23. However, the authors included patients with CKD stage 2-4, patients on peritoneal dialysis and subjects with normal kidney function. In addition, the relative risks were not converted onto a standard scale of effect, which altogether might explain the higher risk for mortality found in the present study.
The link between FGF23, a physiologic bone-derived counter-regulatory hormone for 1,25 dihydroxyvitamin D, and mortality is not fully understood [62, 63] . FGF23 is markedly elevated in ESRD patients (up to 1000-fold) and independently involved in the onset and progression of CKD-related cardiovascular damage, mainly in the heart [64] [65] [66] . However, methodological differences of FGF23 assessment limit the value of observed FGF23-derived organ damage in the clinical setting. Analytical agreement between C-terminal and intact FGF23 is often poor due to calibration differences among assay kits, as well as inter-and intraindividual variation [67] . In the present meta-analysis, the pooled risk for mortality was similar for both C-terminal and intact FGF23 concentrations among patients undergoing hemodialysis. For the interpretation of this result it is important to keep in mind that reported risks were transformed for the comparison of the lower versus the upper third of biomarker distribution. Therefore, a different pattern in prediction capability between C-terminal and intact FGF23 cannot be ruled out when a higher or lower difference in biomarker concentrations among the study populations is compared. As a matter of fact, one included study reported separately the association of C-terminal and intact FGF23 with all-cause mortality and found a 5.7-fold versus a 3.5-fold increase in risk comparing the lower with the upper quartile of the population distribution, respectively [42] . In dialysis patients, however, the agreement between assays determining C-terminal and intact FGF23 is good and both methods are appropriate for FGF23 measurement [68] . In contrast, the concordance of FGF23 assays is low among CKD and pre-dialysis patients, likely due to different patterns of FGF23 cleavage pathways [68, 69] .
In renal transplant patients, both identified studies investigated the relationship of C-terminal FGF23 with mortality and found an up to 3-fold increase in risk for cardiovascular mortality in fully adjusted models [57] . Kidney transplantation is followed by a reduction in circulating FGF23 [70] ; however, a higher baseline cardiovascular risk of kidney graft recipients in addition to multifactorial disease modification and immunosuppressive therapy result in a higher overall risk for mortality in this population setting.
In 2008, Nybo and Rasmussen conducted a systematic review on the relationship of OPG and mortality [71] . A quantitative summary was not performed due to methodological issues, nevertheless, the authors supported the role of OPG as a predictor of cardiovascular disease and mortality. OPG is a soluble tumor necrosis factor superfamily receptor that has been implicated in changes in vessel matrix composition, development of macroangiopathy, plaque destabilization and left ventricular hypertrophy [72, 73] . Hence, the main implication of elevated OPG activity is the promotion and progression of atherosclerotic lesions, which might explain the present finding that OPG is significantly associated with cardiovascular disease-related mortality but not with death from any cause. However, sensitivity analysis showed a significant association of OPG with all-cause mortality after removal of the study conducted by Lee et al. [46] . Subgroup analysis might have provided possible explanations for the difference in outcome risk prediction of OPG but was not possible due to the low number of studies that met the inclusion criteria.
For renal transplant patients, one included study reported a borderline significant predictive value of OPG for death from any cause in multiadjusted risk prediction models [59] . The second study that met the inclusion criteria reported a 5-fold increase in risk for all-cause mortality and a 7-fold increase in risk for cardiovascular mortality; however, the adjustment degree in multivariate models was poor and the precision of study estimate was low [58] .
Available data on the association between Klotho protein, RANK ligand, OPN or BMP-7 and mortality is scarce for both hemodialysis and renal transplant patients. The systematic literature search yielded four studies that investigated the relationship of these biomarkers with mortality in hemodialysis patients, whereas no study recruiting renal graft recipients was identified. None of these biomarkers was significantly related to mortality except for Klotho protein, which was associated with all-cause mortality in one small study including 63 hemodialysis patients [51] . Further investigation is needed in order to gain insight into the predictive value of Klotho protein, RANK ligand, OPN and BMP-7.
The present meta-analysis has to be considered with its strengths and limitations. Studies were eligible if they were published in English, German or Spanish language; however, none of the screened articles had to be removed due to language restriction. The investigated population was a representative sample of patients assembled at a common point in the course of their disease. The systematic search excluded studies that recruited ESRD patients not on hemodialysis or undergoing peritoneal dialysis; however, one included study conducted in 603 subjects contained a minor proportion of patients on peritoneal dialysis (5.5%) [52] . Furthermore, only studies that reported the risk for mortality as time-to-event data were eligible for review in order to reduce risk estimate bias. Nevertheless, one nested case-control study that reported OR was included because a fixed time of follow-up was given, hence, the OR can be assumed to be representative of the HR [42] .
Heterogeneity between studies, publication bias and adjustment degree were evaluated according to established guidelines [31] . Heterogeneity was moderate (<75%) for the quantitative summary of the associations between FGF23 and mortality types and high (!75%) for the pooled HRs of OPG for mortality outcomes, suggesting that the actual pooled estimate for mortality is more modest. Differences in biomarker assays, sample types and reported biomarker units naturally contribute to heterogeneity across studies. In addition, the adjustment for potentially confounding factors in risk prediction models varied largely across studies from univariate analysis to fully adjusted models including cardiovascular risk factors, biochemical laboratory values and established biomarkers of mortality risk. Harmonization of adjustment factors in predictive models is desirable for futures studies. Publication bias was not significant in quantitative summaries of more than 10 studies, nevertheless, selective reporting bias in the literature may have influenced the present findings.
In conclusion, for the comparison of the upper versus the lower third of biomarker distribution, FGF23 is a predictor of all-cause and cardiovascular mortality in ESRD patients undergoing hemodialysis, whereas the predictive value of OPG is restricted to death due to cardiovascular events. Measurement of both biomarkers may be reasonable for additional risk stratification in hemodialysis patients. Further studies are needed in order to gain insight into the prognostic value of biomarkers of vascular calcification in renal transplant patients.
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